BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

N6022: Phase I started

N30 Pharma began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of intravenous N6022 in...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >